ErbB2 is essential in the prevention of dilated cardiomyopathy

Nature Medicine

Volumn 8, Issue 5, 2002, Pages 459-465

  Crone, Steven A ^a,b,c   Zhao, You Yang ^a,b   Fan, Lian ^d   Gu, Yusu ^a,b   Minamisawa, Susumu ^a,b   Liu, Yang ^a,b   Peterson, Kirk L ^a,b   Chen, Ju ^a,b   Kahn, Ronald ^e   Condorelli, Gianluigi ^f   Ross, John ^a,b   Chien, Kenneth R ^a,b   Lee, Kuo Fen ^a,b  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Div of Biology   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOBUTAMINE; PROTEIN BCL XL; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ECHOCARDIOGRAPHY; GENE DELETION; GENE FUNCTION; HEART AFTERLOAD; HEART DILATATION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART SIZE; HEART VENTRICLE; HEART VENTRICLE WALL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE NEU; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; BREAST NEOPLASMS; CARDIOMYOPATHY, DILATED; DOXORUBICIN; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, ESSENTIAL; HEART; HEART RATE; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIUM; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0036099675     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0502-459     Document Type: Article

References (37)

1. The Erb signaling network: Receptor heterodimerization in development and cancer
2. Biochemical and clinical implication of the ErbB/HER signaling network of growth factor receptors
3. The biology of erbB-2/neu/HER-2 and its role in cancer
4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
5. Current and planned clinical trials with trastuzumab (Herceptin)
6. Cardiac toxicity of tanstuzumab (herceptin): Implications for the design of adjuvant trials
7. Ventricular muscle-restricted targeting of the RXRα gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis
8. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression
9. Biochemical correlates of cardiac hypertrophy
10. Loss of a gp 130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
11. Molecular and cellular biology of cardiac hypertrophy and failure
12. Cardiac toxicity of adriamycin-DNA complex and rubidazone: Evaluation by electrocardiogram and endomyocardial biopsy
13. Anthracycline cardiomyopathy monitored by morphologic changes
14. Overview of cardiac pathology in relation to anthracycline cardiotoxicity
15. Biochemical and molecular investigations in respiratory chain deficiencies
16. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophim: A model for duchenne muscular dystrophy
17. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy
18. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy
19. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy
20. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure
21. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression
22. Neuregulin in cardiac hypertrophy in rats with aortic stenosis: Differential expression of ErbB2 and ErbB4 receptors
23. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy
24. Apoptosis: Basic mechanisms and implications for cardiovascular disease
25. High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates
26. Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats
27. Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane
28. 2+ signaling in salivary epithelial cell lines transfected with Bcl-2 and Bcl-XL
29. The anthracycline antineoplastic drugs
30. A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes
31. Requirement for neuregulin receptor ErbB2 in neural and cardiac development
32. ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2 and heregulin-deficient mice
33. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system
34. Neuregulins promote survival and growth of cardiac myocytes: Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes
35. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
36. Transthoracic echocardiography in models of cardiac disease in the mouse
37. Selective requirement of myosin light chain 2v in embryonic heart function